| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Biological Sciences, Rutgers University, 101 Warren St., Newark, NJ 07102, USA; and 2 Departamento Biologia Celular, Facultad de Biologia, Universidad Complutense, Madrid 28040, Spain;
* corresponding author, dganea{at}andromeda.rutgers.edu
The structurally related neuropeptides VIP and PACAP are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the production of pro-inflammatory agents (cytokines, chemokines, and nitric oxide), and stimulate the production of the anti-inflammatory cytokine IL-10. These events are mediated through the VIP/PACAP effects on de novo expression or nuclear translocation of several transcription factors, i.e., NF
B, CREB, c-Jun, JunB, and IRF-1. The in vivo administration of VIP/PACAP results in a similar pattern of cytokine and chemokine modulation, which presumably mediates the protective effect of VIP/PACAP in septic shock. In addition, VIP/PACAP reduce the expression of the co-stimulatory molecules B7.1/B7.2, and the subsequent stimulatory activity of macrophages for T-helper cells. In T-cells expressing specific VIP/PACAP receptors, VIP and PACAP inhibit the expression of FasL through effects on NFB, NFAT, and Egr2/3. The reduction of FasL expression has several biological consequences: inhibition of antigen-induced cell death in CD4 T-cells, inhibition of the FasL-mediated cytotoxicity of CD8 and CD4 effectors against direct and bystander targets, and promotion of long-term memory Th2 cells, through a positive effect on the survival of Th2, but not Th1, effectors. The various biological effects of VIP and PACAP are discussed within the range of a general anti-inflammatory model.
Key words. Neuropeptides, VIP, PACAP, macrophages, T-cell apoptosis, T-cell cytotoxicity, T-cell differentiation
This article has been cited by other articles:
|
|
 |
|
  C. W. Michalski, F. Selvaggi, M. Bartel, T. Mitkus, A. Gorbachevski, T. Giese, P. D. Sebastiano, N. A. Giese, and H. Friess Altered anti-inflammatory response of mononuclear cells to neuropeptide PACAP is associated with deregulation of NF-{kappa}B in chronic pancreatitis Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G50 - G57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bogunovic, S. H. Dave, J. S. Tilstra, D. T. W. Chang, N. Harpaz, H. Xiong, L. F. Mayer, and S. E. Plevy Enteroendocrine cells express functional Toll-like receptors Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1770 - G1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Foster, S. R. Lea, P. M. Preshaw, and J. J. Taylor Pivotal Advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages J. Leukoc. Biol., April 1, 2007; 81(4): 893 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Szema, S. A. Hamidi, S. Lyubsky, K. G. Dickman, S. Mathew, T. Abdel-Razek, J. J. Chen, J. A. Waschek, and S. I. Said Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L880 - L886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. HERRERA, R. FERNANDEZ-MONTESINOS, E. GONZALEZ-REY, M. DELGADO, and D. POZO Protective Role for Plasmid DNA-Mediated VIP Gene Transfer in Non-Obese Diabetic Mice Ann. N.Y. Acad. Sci., July 1, 2006; 1070(1): 337 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-V. TAN, A. COUVINEAU, J. J. LACAPERE, and M. LABURTHE Characterization of the New Photoaffinity Probe (Bz2-K24)-VIP Ann. N.Y. Acad. Sci., July 1, 2006; 1070(1): 575 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohtaki, T. Nakamachi, K. Dohi, Y. Aizawa, A. Takaki, K. Hodoyama, S. Yofu, H. Hashimoto, N. Shintani, A. Baba, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6 PNAS, May 9, 2006; 103(19): 7488 - 7493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ait-Ali, V. Turquier, L. Grumolato, L. Yon, M. Jourdain, D. Alexandre, L. E. Eiden, H. Vaudry, and Y. Anouar The Proinflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-1 Stimulate Neuropeptide Gene Transcription and Secretion in Adrenochromaffin Cells via Activation of Extracellularly Regulated Kinase 1/2 and p38 Protein Kinases, and Activator Protein-1 Transcription Factors Mol. Endocrinol., July 1, 2004; 18(7): 1721 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Voice, S. Donnelly, G. Dorsam, G. Dolganov, S. Paul, and E. J. Goetzl c-Maf and JunB Mediation of Th2 Differentiation Induced by the Type 2 G Protein-Coupled Receptor (VPAC2) for Vasoactive Intestinal Peptide J. Immunol., June 15, 2004; 172(12): 7289 - 7296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-K. V. Cheung, S. Modak, Y. Lin, H. Guo, P. Zanzonico, J. Chung, Y. Zuo, J. Sanderson, S. Wilbert, L. J. Theodore, et al. Single-Chain Fv-Streptavidin Substantially Improved Therapeutic Index in Multistep Targeting Directed at Disialoganglioside GD2 J. Nucl. Med., May 1, 2004; 45(5): 867 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.T. Lundy and G.J. Linden NEUROPEPTIDES AND NEUROGENIC MECHANISMS IN ORAL AND PERIODONTAL INFLAMMATION Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 82 - 98. [Abstract] [Full Text]
|
|
|
|
|
|
H. Jing, E. Vassiliou, and D. Ganea Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells J. Leukoc. Biol., November 1, 2003; 74(5): 868 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-V. Tan, A. Couvineau, J. Van Rampelbergh, and M. Laburthe Photoaffinity Labeling Demonstrates Physical Contact between Vasoactive Intestinal Peptide and the N-terminal Ectodomain of the Human VPAC1 Receptor J. Biol. Chem., September 19, 2003; 278(38): 36531 - 36536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado Inhibition of Interferon (IFN) {gamma}-induced Jak-STAT1 Activation in Microglia by Vasoactive Intestinal Peptide: INHIBITORY EFFECT ON CD40, IFN-INDUCED PROTEIN-10, AND INDUCIBLE NITRIC-OXIDE SYNTHASE EXPRESSION J. Biol. Chem., July 18, 2003; 278(30): 27620 - 27629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, J. Leceta, and D. Ganea Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia J. Leukoc. Biol., January 1, 2003; 73(1): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® | Journal of Dental Research ® | Critical Reviews (1990-2004) |
